Angiogenesis and Tumor Proliferation/Metastasis of Human Colorectal Cancer Cell Line SW620 Transfected with Endocrine Glands-Derived-Vascular Endothelial Growth Factor, As a New Angiogenic Factor

2004 Fiscal Year Final Research Report Summary

• Project/Area Number: 15591393
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: University of Fukui (2004); 福井医科大学 (2003)
• Principal Investigator: GOI Takanori University of Fukui, Faculty of Medical Sciences, Assistant, 医学部, 助手 (60225638)
• Co-Investigator(Kenkyū-buntansha): YAMAGUCHI Akio University of Fukui, Faculty of Medical Sciences, Professor, 医学部, 教授 (10174608)
• Project Period (FY): 2003 – 2004
• Keywords: Colorectal cancer / Angiogenesis / EG-VEGF

Research Abstract

Endocrine glands-derived-venous endothelial growth factor (EG-VEGF) was recently cloned as a new angiogenic factor that selectively acts on the endothelium of endocrine gland cells. The expression of EG-VEGF was comfirmed in all colorectal cancer cell lines. (On the other hand, the expression of EG-VEGF mRNA was not detected in colorectal normal mucosae.)
Tumor proliferation(cecum, s.c.) was significantly higher in the EG-VEGF transfectants than in the control cells. Also, Liver metastatic ratio was higher in the EG-VEGF transfectants than in the control cells. In this study, EG-VEGF may lead to angiogenesis, promoting cell proliferation, and liver metastasis in colorectal cancers. And When the EG-VEGF gene-overexpressing colorectal cancer cell line had been treated with phosphorothioate antisense EG-VEGF oligonucleotides, angiogenesis and tumor growth were inhibited. Angiogenesis factor EG-VEGF indicates that it is a cancer-specific and possibly tissue-specific angiogenesis factor in the large intestine, and suggests that it can be targeted by a novel anti angiogenesis therapy.